Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth

Executive Summary

Record-setting divestment order driven by sheer number of products where firms competed, not size of company that would result from acquisition.

You may also be interested in...



Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products

US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.

Pharma Merger Divestitures: Some Buyers Fail To Replace Generic Products

US FTC analysis of merger remedy orders finds that of 42 on-market generic products that required manufacturing transfer, the buyer was unable to continue to sell 15 products.

Generic Industry Consolidation Illustrated In ANDA Holder List

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel